Fexinidazole Winthrop: Opinion on medicine for use outside EU

fexinidazole

Opinion on medicine for use outside the European Union
Positive opinion

Overview

Fexinidazole Winthrop is a medicine for treating sleeping sickness (African trypanosomiasis) caused by a parasite known as Trypanosoma brucei gambiense. It is intended for use outside the EU.

Sleeping sickness occurs in some parts of Africa and is spread through the bite of infected tsetse flies. In the first few days after being bitten, patients may have symptoms such as fever, headache and rash. Later, they may experience a more severe form of the disease, which affects the nervous system, causing symptoms such as sleep disturbances and changes in behaviour. Without treatment, the disease is usually fatal.

Fexinidazole Winthrop is for patients who are 6 years or older and weigh more than 20 kilograms. It contains the active substance fexinidazole.

Opinion details

Product details
Name of medicinal product
Fexinidazole Winthrop
Agency opinion number
H-W-2320
Opinion status
Positive opinion
Active substance
fexinidazole
International non-proprietary name (INN) or common name
fexinidazole
Therapeutic area (MeSH)
Trypanosomiasis, African
Anatomical therapeutic chemical (ATC) code
P01CA03
Publication details
Opinion holder

sanofi-aventis groupe
54 rue La Boétie
75008  Paris
France

Date of opinion
15/11/2018

Product information

15/11/2018 Fexinidazole Winthrop H-W-2320

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Antiparasitic products, insecticides and repellents

  • Antiprotozoals

  • Agents against leishmaniasis and trypanosomiasis

  • Nitroimidazole derivatives

Therapeutic indication

Fexinidazole Winthrop is indicated for the treatment of both first-stage (haemo-lymphatic) and second-stage (meningo-encephalitic) of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in adults and children ≥ 6 years old and weighing ≥ 20 kg. Fexinidazole should be used in line with official recommendations.

Assessment history

How useful was this page?

Add your rating